胆胰疾病患者血浆中肿瘤抑制性微小RNA的甲基化
Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.
作者信息
Ohtsubo Koushiro, Miyake Kunio, Arai Sachiko, Fukuda Koji, Suzuki Chiaki, Kotani Hiroshi, Tanimoto Azusa, Nishiyama Akihiro, Nanjo Shigeki, Yamashita Kaname, Takeuchi Shinji, Yano Seiji
机构信息
Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Department of Health Sciences, School of Medicine, University of Yamanashi, Chuo, Japan.
出版信息
Cancer Diagn Progn. 2022 May 3;2(3):378-383. doi: 10.21873/cdp.10120. eCollection 2022 May-Jun.
BACKGROUND/AIM: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis of plasma miRNAs to identify miRNAs specific for PBCs.
PATIENTS AND METHODS
Plasma was collected from 80 patients with pancreatic cancer (PC); 18 with biliary tract cancer (BTC) and 28 with BD. Sequences encoding 3 tumor suppressive miRNAs (miR-200a, -200b, and -1247) were PCR amplified and sequenced, and their methylation rates were determined.
RESULTS
The methylation rate of miR-1247 was significantly higher in patients with BTC than in those with BD, and tended to be higher in patients with PC than in those with BD. Furthermore, it was significantly higher in three patients with stages I/II BTC than in those with BD.
CONCLUSION
Methylation of miR-1247 in plasma may be useful to distinguish BTC from BD.
背景/目的：我们之前报道了胆汁中肿瘤抑制性微小RNA（miRNA）的异常甲基化在鉴别胰胆管癌（PBC）与良性胰胆管疾病（BD）方面的作用。在此，我们对血浆miRNA进行甲基化分析，以鉴定PBC特有的miRNA。
患者与方法
收集了80例胰腺癌（PC）患者、18例胆管癌（BTC）患者和28例BD患者的血浆。对编码3种肿瘤抑制性miRNA（miR-200a、-200b和-1247）的序列进行PCR扩增和测序，并测定其甲基化率。
结果
BTC患者中miR-1247的甲基化率显著高于BD患者，PC患者的甲基化率也倾向于高于BD患者。此外，I/II期BTC患者中miR-1247的甲基化率显著高于BD患者。
结论
血浆中miR-1247的甲基化可能有助于鉴别BTC与BD。
Zotero 插件